Igor Sherman, CEO of Alpha Cancer Technologies comments, “Many have tried using conventional expression platforms and have been unsuccessful. This is a truly enabling platform that provides an expanded commercialization pathway for ACT and will allow us to significantly expand our patent life and IP portfolio”
AbSci Closes $15.4 M in Series D Funding to Accelerate Growth and Scale Disruptive Protein PrintingTM Technology, Announces Exclusive Co-Marketing Partnership with KBI Biopharma
VANCOUVER, Washington – January 13, 2020 – AbSci, the Protein Printing™ company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today announced the completion of a $10.4M Series D financing led by KBI...
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators. Culling from a variety of lists that...
European friends, if you have an interest in learning more about AbSci's expression platform, SoluPro. Or would like to hear about AbSci's novel 12-week cell line optimization workflow, reach out to Kole Krieger to schedule a meeting. firstname.lastname@example.org
If you have an interest in learning more about AbSci's expression platform, SoluPro, or would like to hear about AbSci's novel 12-week cell line optimization workflow, reach out to Kole Krieger to schedule some time to meet. email@example.com
“Next-generation antibodies and proteins scaffolds present a roughly $14bn market opportunity by 2024 and getting to clinic six to 15 months sooner is a huge advantage, and a key driver, for partnering with AbSci.”
“This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluProTM can uniquely deliver on this industry need.”
“[SoluPro] enables “tuning” of protein production rates by optimizing for the best protein-folding and titer.”
“Sean McClain skipped the traditional academic route after graduating college…”
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals,” – Andrew J.S. Jones, D. Phil